Results 131 to 140 of about 3,280,724 (167)

Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations.

, 2020
511Background: ERDA, an oral pan-FGFR inhibitor, is approved by the US FDA for pts with metastatic urothelial carcinoma (mUC) with susceptible FGFR3/2 gene alterations and progressed after ≥1 line ...
V. Moreno, Y. Loriot, B. Valderrama, C. Beato, Y. Vano, M. Fleming, I. Durán, S. Siena, J. Tolbert, Anne OHagan, S. Akapame, Yvonne Y. Lau, L. Geoffrois, S. Tagawa, B. Mellado, A. Siefker-Radtke   +15 more
semanticscholar   +1 more source

A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.

, 2020
TPS603Background: ERDA, an oral pan-FGFR inhibitor, is approved by the US FDA for metastatic urothelial carcinoma (mUC) with susceptible FGFR3 or FGFR2 gene alterations and progressed on/ or after ...
G. Steinberg, J. Palou-Redorta, J. Gschwend, B. Tran, Y. Loriot, S. Daneshmand, M. Rouprêt, A. Santiago-Walker, Julie C. Switzky, C. Major, M. Baig, Q. Xia, J. Catto   +12 more
semanticscholar   +1 more source

Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC): Analysis of UNITE database.

Journal of Clinical Oncology
616 Background: The optimal therapy sequencing in aUC with FGFR2/3 alt is unclear. FGFR inhibition may increase Nectin-4 expression. We hypothesized that outcomes with EV would be more favorable when given after E compared to before E in pts with aUC ...
Cindy Y Jiang, Hyunsoo Hwang, T. Jindal, Wei Qiao, Ilana B. Epstein, Charles B. Nguyen, Shilpa Gupta, Sumit A Shah, M. Bilen, Matthew I. Milowsky, C. Hoimes, D. Kilari, Y. Zakharia, H. Emamekhoo, P. Grivas, Joaquim Bellmunt, A. Alva, V. Koshkin, M. Campbell, O. Alhalabi   +19 more
semanticscholar   +1 more source

ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.

, 2020
5015Background: Erdafitinib (JNJ-42756493; ERDA) is the only pan-FGFR kinase inhibitor with US FDA approval for treatment of adults with mUC with susceptible FGFR3/2 alterations (alt) and who progr...
A. Siefker-Radtke, A. Necchi, S. Park, J. García-Donas, R. Huddart, E. Burgess, M. Fleming, A. Rezazadeh, B. Mellado, S. Varlamov, M. Joshi, I. Durán, S. Tagawa, Y. Zakharia, M. Fu, A. Santiago-Walker, M. Monga, Anne OHagan, S. Mosher, Y. Loriot   +19 more
semanticscholar   +1 more source

Perancangan Sistem Informasi Inventory Obat Berbasis Web Pada Apotek Fadhilah Farma

Jurnal Sistem Komputer
This research aims to design a Web-Based Drug Inventory Information System at the Fadhilah Farma Pharmacy. In the era of information technology development, the use of reliable information systems has become an important requirement for health ...
Erda Lusiana, Imilda, Abdus Salam
semanticscholar   +1 more source

Efficacy of erdafitinib in FGFR2/3-altered metastatic urothelial cancer including patients with CDK2NA/B or MTAP loss: Analysis of UNITE study.

Journal of Clinical Oncology
e16571 Background: Erdafitinib (erda) is a fibroblast growth factor receptor (FGFR) inhibitor used in previously-treated FGFR2/3-altered locally advanced/metastatic urothelial cancer (LA/mUC). FGFR2/3 alterations (alts) are present in 15-20% of patients (
Cindy Y Jiang, T. Jindal, Ilana B. Epstein, Charles B. Nguyen, A. Nizam, D. Bakaloudi, A. Taylor, Matthew I. Milowsky, Sumit A Shah, C. Hoimes, M. Bilen, Y. Zakharia, H. Emamekhoo, P. Grivas, Shilpa Gupta, Joaquim Bellmunt, A. Alva, V. Koshkin, O. Alhalabi, Matthew T. Campbell   +19 more
semanticscholar   +1 more source

The chemistry of americium: Wallace W. Schultz; ERDA Critical Review Series, TID-26971; published by Technical Information Center, US ERDA Oak Ridge, October 1976; pp. vii + 291; price US $ 6 (foreign: US $ 8.50)

, 1978
F. Weigel
semanticscholar   +1 more source

Archive of Digitized Analog Boomer Seismic-Reflection Data Collected During U.S. Geological Survey Cruises Erda 90-1_HC, Erda 90-1_PBP, and Erda 91-3 in Mississippi Sound, June 1990 and September 1991

, 2017
S. Bosse, J. Flocks, A. Forde
semanticscholar   +1 more source

Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.

, 2018
Y. Loriot, A. Necchi, S. Park, J. García-Donas, R. Huddart, E. Burgess, M. Fleming, A. Rezazadeh, B. Mellado, S. Varlamov, M. Joshi, I. Durán, Anne OHagan, A. Avadhani, B. Zhong, K. Stuyckens, A. Dosne, A. Siefker-Radtke   +17 more
semanticscholar   +1 more source

Analysis of AlN thin films by combining TOF-ERDA and NRB techniques

, 1996
J. Jokinen, P. Haussalo, J. Keinonen, M. Ritala, Diana Riihelä, M. Leskelä   +5 more
semanticscholar   +1 more source